Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 11/20 | 0.53 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.46 |
| ▸ | FBP1 | P09467 | 1/20 | 0.46 |
| ▸ | TNF | P01375 | 1/20 | 0.45 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.45 |
| ▸ | UBE2T | Q9NPD8 | 1/20 | 0.44 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25831137 | 0.90 | LOXL2 (0.49) | CASRLOXL2FBP1TNFNOD1 | |
| SCHEMBL23452696 | 0.90 | CASR (0.48) | CASRLOXL2FBP1TNFNOD1 | |
| SCHEMBL20312885 | 0.86 | CASR (0.50) | CASRFBP1TNFNOD1UBE2T | |
| SCHEMBL12545796 | 0.86 | CASR (0.53) | CASRFBP1TNFNOD1UBE2T | |
| SCHEMBL30731332 | 0.83 | CASR (0.57) | CASRFBP1TNFNOD1CYP1A2 | |
| SCHEMBL23453157 | 0.81 | CASR (0.46) | CASRFBP1TNFNOD1CYP1A2 | |
| SCHEMBL227210 | 0.81 | CASR (0.58) | CASRFBP1TNFNOD1 | |
| SCHEMBL108180 | 0.81 | CASR (0.58) | CASRFBP1TNFNOD1 | |
| SCHEMBL30731281 | 0.81 | CASR (0.55) | CASRFBP1UBE2TASIC3 | |
| SCHEMBL23453144 | 0.80 | CASR (0.45) | CASRFBP1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200046845-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. | 2020-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200046845-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CDR2, DDOST, GALC | CASR 3034/4885LOXL2 3507/4885FBP1 1576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.